Gilbert G G Donders1, Scott A Halperin, Roland Devlieger, Sherryl Baker, Pietro Forte, Frederick Wittke, Karen S Slobod, Peter M Dull. 1. Femicare Clinical Research for Women and the Department of Obstetrics and Gynecology, Regional Hospital H Hart, Tienen, University Hospital Antwerpen, Antwerp, and the Department of Obstetrics and Gynaecology, University Hospitals KULeuven, Leuven, Belgium; the Canadian Center for Vaccinology, Department of Pediatrics and Microbiology and Immunology, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada; GlaxoSmithKline LLC, Cambridge, Massachusetts; and Novartis Vaccines and Diagnostics S.r.l, Siena, Italy-a GSK company.
Abstract
OBJECTIVE: To evaluate the safety and immunogenicity of an investigational trivalent group B streptococcal vaccine in pregnant women and antibody transfer to their newborns. METHODS: The primary outcome of this observer-blind, randomized study was to estimate placental antibody transfer rates at birth. Secondary outcomes included measurement of serotype-specific antibodies at screening, 30 days postvaccination, at delivery, and 91 days postpartum, infant antibody levels at 3 months of age, the potential effect on routine infant diphtheria vaccination at 1 month after the third infant series dose, and safety in mother and infant participants through at least 5 months postpartum. Sample size was based on 60 participants in the vaccine group giving a probability of observing at least one adverse event of 90% if the actual rate of the event was 3.8%. RESULTS:From September 2011 to October 2013, 86 pregnant women were allocated in a 3:2 ratio to receive an investigational group B streptococcal vaccine containing glycoconjugates of serotypes Ia, Ib, and III or placebo. Demographics were similar across groups. Transfer ratios were 66-79% and maternal geometric mean concentrations increased 16-, 23-, and 20-fold by delivery against serotypes Ia, Ib, and III, respectively, Women with no detectable antibodies at inclusion had lower responses than those with detectable antibodies. Three months after birth, infant antibody concentrations were 22-25% of birth levels. Antidiphtheria geometric mean concentrations were similar across groups. In the vaccine and placebo groups, 32 of 51 women (63%) and 26 of 35 women (74%) reported adverse effects, respectively. CONCLUSION: The investigational vaccine was well-tolerated without safety signals in recipients and their infants or interference with routine infant diphtheria vaccination, although further studies on safety and effectiveness are needed. The investigational vaccine was immunogenic for all serotypes, particularly among women with detectable antibody levels at baseline. Antibody transfer to neonates was at similar levels to other maternally administered polysaccharide vaccines. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01446289.
RCT Entities:
OBJECTIVE: To evaluate the safety and immunogenicity of an investigational trivalent group B streptococcal vaccine in pregnant women and antibody transfer to their newborns. METHODS: The primary outcome of this observer-blind, randomized study was to estimate placental antibody transfer rates at birth. Secondary outcomes included measurement of serotype-specific antibodies at screening, 30 days postvaccination, at delivery, and 91 days postpartum, infant antibody levels at 3 months of age, the potential effect on routine infant diphtheria vaccination at 1 month after the third infant series dose, and safety in mother and infantparticipants through at least 5 months postpartum. Sample size was based on 60 participants in the vaccine group giving a probability of observing at least one adverse event of 90% if the actual rate of the event was 3.8%. RESULTS: From September 2011 to October 2013, 86 pregnant women were allocated in a 3:2 ratio to receive an investigational group B streptococcal vaccine containing glycoconjugates of serotypes Ia, Ib, and III or placebo. Demographics were similar across groups. Transfer ratios were 66-79% and maternal geometric mean concentrations increased 16-, 23-, and 20-fold by delivery against serotypes Ia, Ib, and III, respectively, Women with no detectable antibodies at inclusion had lower responses than those with detectable antibodies. Three months after birth, infant antibody concentrations were 22-25% of birth levels. Antidiphtheria geometric mean concentrations were similar across groups. In the vaccine and placebo groups, 32 of 51 women (63%) and 26 of 35 women (74%) reported adverse effects, respectively. CONCLUSION: The investigational vaccine was well-tolerated without safety signals in recipients and their infants or interference with routine infant diphtheria vaccination, although further studies on safety and effectiveness are needed. The investigational vaccine was immunogenic for all serotypes, particularly among women with detectable antibody levels at baseline. Antibody transfer to neonates was at similar levels to other maternally administered polysaccharide vaccines. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01446289.
Authors: Srinivas Acharya Nanduri; Susan Petit; Chad Smelser; Mirasol Apostol; Nisha B Alden; Lee H Harrison; Ruth Lynfield; Paula S Vagnone; Kari Burzlaff; Nancy L Spina; Elizabeth M Dufort; William Schaffner; Ann R Thomas; Monica M Farley; Jennifer H Jain; Tracy Pondo; Lesley McGee; Bernard W Beall; Stephanie J Schrag Journal: JAMA Pediatr Date: 2019-03-01 Impact factor: 16.193
Authors: Sharon L Hillier; Patricia Ferrieri; Morven S Edwards; Marian Ewell; Daron Ferris; Paul Fine; Vincent Carey; Leslie Meyn; Dakota Hoagland; Dennis L Kasper; Lawrence C Paoletti; Heather Hill; Carol J Baker Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079
Authors: Thomas A Hooven; Andrew J Catomeris; Leor H Akabas; Tara M Randis; Duncan J Maskell; Sarah E Peters; Sandra Ott; Ivette Santana-Cruz; Luke J Tallon; Hervé Tettelin; Adam J Ratner Journal: BMC Genomics Date: 2016-05-26 Impact factor: 3.969
Authors: Robert S Heyderman; Shabir A Madhi; Neil French; Clare Cutland; Bagrey Ngwira; Doris Kayambo; Robert Mboizi; Anthonet Koen; Lisa Jose; Morounfolu Olugbosi; Frederik Wittke; Karen Slobod; Peter M Dull Journal: Lancet Infect Dis Date: 2016-02-08 Impact factor: 71.421